As imaging continues to evolve from a supportive function to a critical determinant of trial success, Pharmaceutical and Biotech companies are under increasing pressure to ensure precision, consistency, and regulatory readiness. In this environment, selecting the right iCRO partner is not just important — it is strategic.

RadMD distinguishes itself by operating not simply as a vendor, but as a “Partner” -an extension of your Clinical Team bringing deep expertise, accountability, and a proactive approach to every engagement.

What is RadMD’s mission?

RadMD’s mission is to deliver scientifically rigorous, operationally precise, and regulatory-ready imaging leadership that enables sponsors to move forward with clarity and confidence.

By integrating medical, scientific, and operational expertise, RadMD ensures that imaging endpoints are not only well-designed, but also consistently executed across all sites and phases of development. Built to support complex, multi-phase global studies, RadMD pairs experienced medical leadership with regulatory-ready execution.

This model is specifically designed to reduce variability, proactively address risks, and deliver high-quality imaging data that withstands regulatory scrutiny and supports critical development decisions.

What services does RadMD offer?

RadMD provides comprehensive iCRO imaging solutions that support the full lifecycle of clinical trials (Phase 1 to Phase 4). Together, these capabilities ensure that imaging data is consistently acquired, managed, and interpreted — minimizing variability and maximizing confidence in study outcomes.

What differentiates RadMD from other imaging providers?

RadMD’s differentiation lies in its deliberate focus on expertise, accountability, and partnership. Each engagement is led by an experienced member of the Medical Affairs Team who remain actively involved, ensuring continuity and informed decision-making throughout the study and project.

Unlike other imaging, volume-driven providers, RadMD offers a high-touch, flexible model that prioritizes quality over scale — without compromising the scientific rigor required for regulatory-grade imaging data.

Pharmaceutical and Biotech companies benefit from:

This approach results in stronger collaboration, faster issue resolution, and ultimately, more reliable and defensible imaging endpoints.

Who does RadMD work with?

RadMD works with clients across the pharmaceutical, biotechnology and CRO industries. This diversity enables RadMD to tailor its approach — whether supporting complex global programs or helping emerging companies establish a strong clinical and regulatory foundation.

Where does RadMD operate?

RadMD supports clinical trials globally, supporting sites in more than 70 countries and over 1,000 research sites worldwide.

The company’s headquarters are located in Conshohocken, Pennsylvania, providing close proximity to the U.S. life sciences corridor while supporting sponsors and clinical trials across North America, Europe, and Asia.

Looking ahead

As imaging biomarkers and advanced imaging technologies continue to evolve, imaging will play an increasingly important role in clinical trial endpoints, patient selection, and treatment monitoring.

RadMD is committed to staying at the forefront of these advancements — helping sponsors navigate increasing complexity with confidence through medical and scientific expertise, operational excellence, and a deeply collaborative approach.

For Pharmaceutical and Biotech companies, and CROs seeking a trusted imaging partner who brings both strategic insight and executional excellence, RadMD is your “Partner of Choice”

If you would like to connect with RadMD’s leadership team to discuss how we can support your upcoming clinical trials, please contact us at info@rad-md.net to schedule a call.

Connect with RadMD on Scientist.com